Deltex Medical Group PLC Turner Pope Investor Evening

TIDMDEMG

Deltex Medical Group PLC

03 May 2019

3 May 2019

"Deltex Medical Group plc

("Deltex Medical" or the "Company")

Turner Pope Investor Evening

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), is pleased to announce that Andy Mears, the Company's Chief Executive Officer, will be presenting at an investor evening hosted by Turner Pope Investments (TPI) Ltd on Monday 13 May 2019. The event will be held in London, EC2 and will commence at 5pm.

To register your interest, please email [e-mail] or call on 0203 621 4124.

For further information, please contact: -

 
 Deltex Medical Group plc                 01243 774 837 
 Nigel Keen, Chairman                     [e-mail] 
 Andy Mears, Chief Executive 
 Jonathan Shaw, Group Finance Director 
 
 
   Nominated Adviser & Broker 
 Arden Partners plc                       020 7614 5900 
 Ciaran Walsh 
  Dan Gee-Summons 
 
 
 Joint Broker 
 Turner Pope Investments (TPI) 
  Ltd                                     0203 621 4120 
 Andy Thacker                             [e-mail] 
 

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary oesophageal doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity in the central circulation in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures such changes in 'real time'. Deltex Medical is the only company in the enhanced haemodynamic space to have built a robust and credible evidence base demonstrating both the clinical and economic benefits of its core technology, TrueVue Doppler. This technology has been proven in a wide range of clinical trials to reduce complications suffered by patients after surgery and consequently save hospitals the costs of treating those complications.

Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely non-invasive monitoring technology which transmits low magnitude, high frequency electrical signals through the thorax and measures the changes to this signal when the heart pumps blood. TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

Group goal

Haemodynamic management is now becoming widely accepted as an important part of the anaesthesia protocol for surgical patients. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform - a 'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition as well as the skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK and the USA, and through distribution arrangements in approximately 40 other countries.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRABDGDUXUGBGCX

(END) Dow Jones Newswires

May 03, 2019 08:57 ET (12:57 GMT)